0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cancer Immunotherapy Drug Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-26L14057
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Cancer Immunotherapy Drug Market Research Report 2023
BUY CHAPTERS

Global Cancer Immunotherapy Drug Market Research Report 2025

Code: QYRE-Auto-26L14057
Report
May 2025
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cancer Immunotherapy Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Cancer Immunotherapy Drug Market

Cancer Immunotherapy Drug Market

The global market for Cancer Immunotherapy Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Cancer Immunotherapy Drugs are medications used in the treatment of cancer. These drugs harness the body"s immune system to target and destroy cancer cells. Immunotherapy drugs are designed to boost the body"s natural defenses against cancer and are used in various forms, including immune checkpoint inhibitors and CAR-T cell therapies.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cancer Immunotherapy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Immunotherapy Drug.
The Cancer Immunotherapy Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Immunotherapy Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Immunotherapy Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Cancer Immunotherapy Drug Market Report

Report Metric Details
Report Name Cancer Immunotherapy Drug Market
CAGR 5%
Segment by Type
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Autolus Therapeutics plc, BeiGene, bluebird bio, Inc., Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Gilead Sciences, Inc., Incyte Corporation, Jiangsu Hengrui Medicine, Juno Pharmaceuticals Pty Ltd., Medimmune, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Roche Holding AG
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Cancer Immunotherapy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Cancer Immunotherapy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Cancer Immunotherapy Drug Market report?

Ans: The main players in the Cancer Immunotherapy Drug Market are Autolus Therapeutics plc, BeiGene, bluebird bio, Inc., Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Gilead Sciences, Inc., Incyte Corporation, Jiangsu Hengrui Medicine, Juno Pharmaceuticals Pty Ltd., Medimmune, LLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Roche Holding AG

What are the Application segmentation covered in the Cancer Immunotherapy Drug Market report?

Ans: The Applications covered in the Cancer Immunotherapy Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Cancer Immunotherapy Drug Market report?

Ans: The Types covered in the Cancer Immunotherapy Drug Market report are PD-1 Inhibitor, PDL-1 Inhibitor, T-Cell Stimulant, CTLA Antibody

Recommended Reports

Cancer Drug Therapy

Cancer Diagnosis

Immunotherapy & Checkpoint

1 Cancer Immunotherapy Drug Market Overview
1.1 Product Definition
1.2 Cancer Immunotherapy Drug by Type
1.2.1 Global Cancer Immunotherapy Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 PD-1 Inhibitor
1.2.3 PDL-1 Inhibitor
1.2.4 T-Cell Stimulant
1.2.5 CTLA Antibody
1.3 Cancer Immunotherapy Drug by Application
1.3.1 Global Cancer Immunotherapy Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Cancer Immunotherapy Drug Market Size Estimates and Forecasts
1.4.1 Global Cancer Immunotherapy Drug Revenue 2020-2031
1.4.2 Global Cancer Immunotherapy Drug Sales 2020-2031
1.4.3 Global Cancer Immunotherapy Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Cancer Immunotherapy Drug Market Competition by Manufacturers
2.1 Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Cancer Immunotherapy Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Cancer Immunotherapy Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Cancer Immunotherapy Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Immunotherapy Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Immunotherapy Drug, Product Type & Application
2.7 Global Key Manufacturers of Cancer Immunotherapy Drug, Date of Enter into This Industry
2.8 Global Cancer Immunotherapy Drug Market Competitive Situation and Trends
2.8.1 Global Cancer Immunotherapy Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Cancer Immunotherapy Drug Players Market Share by Revenue
2.8.3 Global Cancer Immunotherapy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Cancer Immunotherapy Drug Market Scenario by Region
3.1 Global Cancer Immunotherapy Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Cancer Immunotherapy Drug Sales by Region: 2020-2031
3.2.1 Global Cancer Immunotherapy Drug Sales by Region: 2020-2025
3.2.2 Global Cancer Immunotherapy Drug Sales by Region: 2026-2031
3.3 Global Cancer Immunotherapy Drug Revenue by Region: 2020-2031
3.3.1 Global Cancer Immunotherapy Drug Revenue by Region: 2020-2025
3.3.2 Global Cancer Immunotherapy Drug Revenue by Region: 2026-2031
3.4 North America Cancer Immunotherapy Drug Market Facts & Figures by Country
3.4.1 North America Cancer Immunotherapy Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Cancer Immunotherapy Drug Sales by Country (2020-2031)
3.4.3 North America Cancer Immunotherapy Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cancer Immunotherapy Drug Market Facts & Figures by Country
3.5.1 Europe Cancer Immunotherapy Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Cancer Immunotherapy Drug Sales by Country (2020-2031)
3.5.3 Europe Cancer Immunotherapy Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Immunotherapy Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Cancer Immunotherapy Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Cancer Immunotherapy Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Cancer Immunotherapy Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Cancer Immunotherapy Drug Market Facts & Figures by Country
3.7.1 Latin America Cancer Immunotherapy Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Cancer Immunotherapy Drug Sales by Country (2020-2031)
3.7.3 Latin America Cancer Immunotherapy Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Immunotherapy Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Immunotherapy Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Cancer Immunotherapy Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cancer Immunotherapy Drug Sales by Type (2020-2031)
4.1.1 Global Cancer Immunotherapy Drug Sales by Type (2020-2025)
4.1.2 Global Cancer Immunotherapy Drug Sales by Type (2026-2031)
4.1.3 Global Cancer Immunotherapy Drug Sales Market Share by Type (2020-2031)
4.2 Global Cancer Immunotherapy Drug Revenue by Type (2020-2031)
4.2.1 Global Cancer Immunotherapy Drug Revenue by Type (2020-2025)
4.2.2 Global Cancer Immunotherapy Drug Revenue by Type (2026-2031)
4.2.3 Global Cancer Immunotherapy Drug Revenue Market Share by Type (2020-2031)
4.3 Global Cancer Immunotherapy Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Cancer Immunotherapy Drug Sales by Application (2020-2031)
5.1.1 Global Cancer Immunotherapy Drug Sales by Application (2020-2025)
5.1.2 Global Cancer Immunotherapy Drug Sales by Application (2026-2031)
5.1.3 Global Cancer Immunotherapy Drug Sales Market Share by Application (2020-2031)
5.2 Global Cancer Immunotherapy Drug Revenue by Application (2020-2031)
5.2.1 Global Cancer Immunotherapy Drug Revenue by Application (2020-2025)
5.2.2 Global Cancer Immunotherapy Drug Revenue by Application (2026-2031)
5.2.3 Global Cancer Immunotherapy Drug Revenue Market Share by Application (2020-2031)
5.3 Global Cancer Immunotherapy Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Autolus Therapeutics plc
6.1.1 Autolus Therapeutics plc Company Information
6.1.2 Autolus Therapeutics plc Description and Business Overview
6.1.3 Autolus Therapeutics plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Autolus Therapeutics plc Cancer Immunotherapy Drug Product Portfolio
6.1.5 Autolus Therapeutics plc Recent Developments/Updates
6.2 BeiGene
6.2.1 BeiGene Company Information
6.2.2 BeiGene Description and Business Overview
6.2.3 BeiGene Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 BeiGene Cancer Immunotherapy Drug Product Portfolio
6.2.5 BeiGene Recent Developments/Updates
6.3 bluebird bio, Inc.
6.3.1 bluebird bio, Inc. Company Information
6.3.2 bluebird bio, Inc. Description and Business Overview
6.3.3 bluebird bio, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 bluebird bio, Inc. Cancer Immunotherapy Drug Product Portfolio
6.3.5 bluebird bio, Inc. Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Company Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bristol-Myers Squibb Cancer Immunotherapy Drug Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Celgene Corporation
6.5.1 Celgene Corporation Company Information
6.5.2 Celgene Corporation Description and Business Overview
6.5.3 Celgene Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Celgene Corporation Cancer Immunotherapy Drug Product Portfolio
6.5.5 Celgene Corporation Recent Developments/Updates
6.6 AstraZeneca plc
6.6.1 AstraZeneca plc Company Information
6.6.2 AstraZeneca plc Description and Business Overview
6.6.3 AstraZeneca plc Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AstraZeneca plc Cancer Immunotherapy Drug Product Portfolio
6.6.5 AstraZeneca plc Recent Developments/Updates
6.7 Gilead Sciences, Inc.
6.7.1 Gilead Sciences, Inc. Company Information
6.7.2 Gilead Sciences, Inc. Description and Business Overview
6.7.3 Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Gilead Sciences, Inc. Cancer Immunotherapy Drug Product Portfolio
6.7.5 Gilead Sciences, Inc. Recent Developments/Updates
6.8 Incyte Corporation
6.8.1 Incyte Corporation Company Information
6.8.2 Incyte Corporation Description and Business Overview
6.8.3 Incyte Corporation Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Incyte Corporation Cancer Immunotherapy Drug Product Portfolio
6.8.5 Incyte Corporation Recent Developments/Updates
6.9 Jiangsu Hengrui Medicine
6.9.1 Jiangsu Hengrui Medicine Company Information
6.9.2 Jiangsu Hengrui Medicine Description and Business Overview
6.9.3 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product Portfolio
6.9.5 Jiangsu Hengrui Medicine Recent Developments/Updates
6.10 Juno Pharmaceuticals Pty Ltd.
6.10.1 Juno Pharmaceuticals Pty Ltd. Company Information
6.10.2 Juno Pharmaceuticals Pty Ltd. Description and Business Overview
6.10.3 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product Portfolio
6.10.5 Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
6.11 Medimmune, LLC
6.11.1 Medimmune, LLC Company Information
6.11.2 Medimmune, LLC Description and Business Overview
6.11.3 Medimmune, LLC Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Medimmune, LLC Cancer Immunotherapy Drug Product Portfolio
6.11.5 Medimmune, LLC Recent Developments/Updates
6.12 Merck & Co., Inc.
6.12.1 Merck & Co., Inc. Company Information
6.12.2 Merck & Co., Inc. Description and Business Overview
6.12.3 Merck & Co., Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Merck & Co., Inc. Cancer Immunotherapy Drug Product Portfolio
6.12.5 Merck & Co., Inc. Recent Developments/Updates
6.13 Novartis AG
6.13.1 Novartis AG Company Information
6.13.2 Novartis AG Description and Business Overview
6.13.3 Novartis AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Novartis AG Cancer Immunotherapy Drug Product Portfolio
6.13.5 Novartis AG Recent Developments/Updates
6.14 Pfizer, Inc.
6.14.1 Pfizer, Inc. Company Information
6.14.2 Pfizer, Inc. Description and Business Overview
6.14.3 Pfizer, Inc. Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Pfizer, Inc. Cancer Immunotherapy Drug Product Portfolio
6.14.5 Pfizer, Inc. Recent Developments/Updates
6.15 Roche Holding AG
6.15.1 Roche Holding AG Company Information
6.15.2 Roche Holding AG Description and Business Overview
6.15.3 Roche Holding AG Cancer Immunotherapy Drug Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Roche Holding AG Cancer Immunotherapy Drug Product Portfolio
6.15.5 Roche Holding AG Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Immunotherapy Drug Industry Chain Analysis
7.2 Cancer Immunotherapy Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Immunotherapy Drug Production Mode & Process Analysis
7.4 Cancer Immunotherapy Drug Sales and Marketing
7.4.1 Cancer Immunotherapy Drug Sales Channels
7.4.2 Cancer Immunotherapy Drug Distributors
7.5 Cancer Immunotherapy Drug Customer Analysis
8 Cancer Immunotherapy Drug Market Dynamics
8.1 Cancer Immunotherapy Drug Industry Trends
8.2 Cancer Immunotherapy Drug Market Drivers
8.3 Cancer Immunotherapy Drug Market Challenges
8.4 Cancer Immunotherapy Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Cancer Immunotherapy Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Cancer Immunotherapy Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Cancer Immunotherapy Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Cancer Immunotherapy Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Cancer Immunotherapy Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Cancer Immunotherapy Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Cancer Immunotherapy Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Cancer Immunotherapy Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Cancer Immunotherapy Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Cancer Immunotherapy Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Cancer Immunotherapy Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Cancer Immunotherapy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapy Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Cancer Immunotherapy Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Cancer Immunotherapy Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Cancer Immunotherapy Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Cancer Immunotherapy Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Cancer Immunotherapy Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Cancer Immunotherapy Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Cancer Immunotherapy Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Cancer Immunotherapy Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Cancer Immunotherapy Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Cancer Immunotherapy Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Cancer Immunotherapy Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Cancer Immunotherapy Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Cancer Immunotherapy Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Cancer Immunotherapy Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Cancer Immunotherapy Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Cancer Immunotherapy Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Cancer Immunotherapy Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Cancer Immunotherapy Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Cancer Immunotherapy Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Cancer Immunotherapy Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Cancer Immunotherapy Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Cancer Immunotherapy Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Cancer Immunotherapy Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Cancer Immunotherapy Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Cancer Immunotherapy Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Cancer Immunotherapy Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Cancer Immunotherapy Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Cancer Immunotherapy Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Cancer Immunotherapy Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Cancer Immunotherapy Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Cancer Immunotherapy Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Cancer Immunotherapy Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Cancer Immunotherapy Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Cancer Immunotherapy Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Cancer Immunotherapy Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Cancer Immunotherapy Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Cancer Immunotherapy Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Cancer Immunotherapy Drug Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Cancer Immunotherapy Drug Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Cancer Immunotherapy Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Cancer Immunotherapy Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Cancer Immunotherapy Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Cancer Immunotherapy Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Cancer Immunotherapy Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Cancer Immunotherapy Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Cancer Immunotherapy Drug Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Cancer Immunotherapy Drug Price (US$/Unit) by Application (2026-2031)
 Table 70. Autolus Therapeutics plc Company Information
 Table 71. Autolus Therapeutics plc Description and Business Overview
 Table 72. Autolus Therapeutics plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Autolus Therapeutics plc Cancer Immunotherapy Drug Product
 Table 74. Autolus Therapeutics plc Recent Developments/Updates
 Table 75. BeiGene Company Information
 Table 76. BeiGene Description and Business Overview
 Table 77. BeiGene Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. BeiGene Cancer Immunotherapy Drug Product
 Table 79. BeiGene Recent Developments/Updates
 Table 80. bluebird bio, Inc. Company Information
 Table 81. bluebird bio, Inc. Description and Business Overview
 Table 82. bluebird bio, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. bluebird bio, Inc. Cancer Immunotherapy Drug Product
 Table 84. bluebird bio, Inc. Recent Developments/Updates
 Table 85. Bristol-Myers Squibb Company Information
 Table 86. Bristol-Myers Squibb Description and Business Overview
 Table 87. Bristol-Myers Squibb Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Bristol-Myers Squibb Cancer Immunotherapy Drug Product
 Table 89. Bristol-Myers Squibb Recent Developments/Updates
 Table 90. Celgene Corporation Company Information
 Table 91. Celgene Corporation Description and Business Overview
 Table 92. Celgene Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Celgene Corporation Cancer Immunotherapy Drug Product
 Table 94. Celgene Corporation Recent Developments/Updates
 Table 95. AstraZeneca plc Company Information
 Table 96. AstraZeneca plc Description and Business Overview
 Table 97. AstraZeneca plc Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. AstraZeneca plc Cancer Immunotherapy Drug Product
 Table 99. AstraZeneca plc Recent Developments/Updates
 Table 100. Gilead Sciences, Inc. Company Information
 Table 101. Gilead Sciences, Inc. Description and Business Overview
 Table 102. Gilead Sciences, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Gilead Sciences, Inc. Cancer Immunotherapy Drug Product
 Table 104. Gilead Sciences, Inc. Recent Developments/Updates
 Table 105. Incyte Corporation Company Information
 Table 106. Incyte Corporation Description and Business Overview
 Table 107. Incyte Corporation Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Incyte Corporation Cancer Immunotherapy Drug Product
 Table 109. Incyte Corporation Recent Developments/Updates
 Table 110. Jiangsu Hengrui Medicine Company Information
 Table 111. Jiangsu Hengrui Medicine Description and Business Overview
 Table 112. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Jiangsu Hengrui Medicine Cancer Immunotherapy Drug Product
 Table 114. Jiangsu Hengrui Medicine Recent Developments/Updates
 Table 115. Juno Pharmaceuticals Pty Ltd. Company Information
 Table 116. Juno Pharmaceuticals Pty Ltd. Description and Business Overview
 Table 117. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Juno Pharmaceuticals Pty Ltd. Cancer Immunotherapy Drug Product
 Table 119. Juno Pharmaceuticals Pty Ltd. Recent Developments/Updates
 Table 120. Medimmune, LLC Company Information
 Table 121. Medimmune, LLC Description and Business Overview
 Table 122. Medimmune, LLC Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Medimmune, LLC Cancer Immunotherapy Drug Product
 Table 124. Medimmune, LLC Recent Developments/Updates
 Table 125. Merck & Co., Inc. Company Information
 Table 126. Merck & Co., Inc. Description and Business Overview
 Table 127. Merck & Co., Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Merck & Co., Inc. Cancer Immunotherapy Drug Product
 Table 129. Merck & Co., Inc. Recent Developments/Updates
 Table 130. Novartis AG Company Information
 Table 131. Novartis AG Description and Business Overview
 Table 132. Novartis AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Novartis AG Cancer Immunotherapy Drug Product
 Table 134. Novartis AG Recent Developments/Updates
 Table 135. Pfizer, Inc. Company Information
 Table 136. Pfizer, Inc. Description and Business Overview
 Table 137. Pfizer, Inc. Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Pfizer, Inc. Cancer Immunotherapy Drug Product
 Table 139. Pfizer, Inc. Recent Developments/Updates
 Table 140. Roche Holding AG Company Information
 Table 141. Roche Holding AG Description and Business Overview
 Table 142. Roche Holding AG Cancer Immunotherapy Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Roche Holding AG Cancer Immunotherapy Drug Product
 Table 144. Roche Holding AG Recent Developments/Updates
 Table 145. Key Raw Materials Lists
 Table 146. Raw Materials Key Suppliers Lists
 Table 147. Cancer Immunotherapy Drug Distributors List
 Table 148. Cancer Immunotherapy Drug Customers List
 Table 149. Cancer Immunotherapy Drug Market Trends
 Table 150. Cancer Immunotherapy Drug Market Drivers
 Table 151. Cancer Immunotherapy Drug Market Challenges
 Table 152. Cancer Immunotherapy Drug Market Restraints
 Table 153. Research Programs/Design for This Report
 Table 154. Key Data Information from Secondary Sources
 Table 155. Key Data Information from Primary Sources
 Table 156. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Cancer Immunotherapy Drug
 Figure 2. Global Cancer Immunotherapy Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Cancer Immunotherapy Drug Market Share by Type: 2024 & 2031
 Figure 4. PD-1 Inhibitor Product Picture
 Figure 5. PDL-1 Inhibitor Product Picture
 Figure 6. T-Cell Stimulant Product Picture
 Figure 7. CTLA Antibody Product Picture
 Figure 8. Global Cancer Immunotherapy Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Cancer Immunotherapy Drug Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Global Cancer Immunotherapy Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Cancer Immunotherapy Drug Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Cancer Immunotherapy Drug Sales (2020-2031) & (K Units)
 Figure 16. Global Cancer Immunotherapy Drug Average Price (US$/Unit) & (2020-2031)
 Figure 17. Cancer Immunotherapy Drug Report Years Considered
 Figure 18. Cancer Immunotherapy Drug Sales Share by Manufacturers in 2024
 Figure 19. Global Cancer Immunotherapy Drug Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Cancer Immunotherapy Drug Players: Market Share by Revenue in Cancer Immunotherapy Drug in 2024
 Figure 21. Cancer Immunotherapy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Cancer Immunotherapy Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Cancer Immunotherapy Drug Sales Market Share by Country (2020-2031)
 Figure 24. North America Cancer Immunotherapy Drug Revenue Market Share by Country (2020-2031)
 Figure 25. United States Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Cancer Immunotherapy Drug Sales Market Share by Country (2020-2031)
 Figure 28. Europe Cancer Immunotherapy Drug Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Cancer Immunotherapy Drug Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Cancer Immunotherapy Drug Revenue Market Share by Region (2020-2031)
 Figure 36. China Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Cancer Immunotherapy Drug Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Cancer Immunotherapy Drug Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Cancer Immunotherapy Drug Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Cancer Immunotherapy Drug Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Cancer Immunotherapy Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Cancer Immunotherapy Drug by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Cancer Immunotherapy Drug by Type (2020-2031)
 Figure 55. Global Cancer Immunotherapy Drug Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Cancer Immunotherapy Drug by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Cancer Immunotherapy Drug by Application (2020-2031)
 Figure 58. Global Cancer Immunotherapy Drug Price (US$/Unit) by Application (2020-2031)
 Figure 59. Cancer Immunotherapy Drug Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS